MUC5AC and bacterial infectious disease: Our data in mice now provide justification for human studies to evaluate the role of repurposing these agents for use in COPD exacerbations to inhibit mucin production that could theoretically suppress airway inflammation, reduce secondary bacterial infection, and diminish exacerbation severity.